Siemens Healthineers (OTCMKTS:SMMNY) Rating Lowered to “Strong Sell” at Zacks Research

Siemens Healthineers (OTCMKTS:SMMNY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday, Zacks reports.

A number of other brokerages have also commented on SMMNY. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Siemens Healthineers in a research note on Tuesday, August 18th. Citigroup reaffirmed a “buy” rating on shares of Siemens Healthineers in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Siemens Healthineers Stock Performance

Shares of Siemens Healthineers stock opened at $21.29 on Thursday. The business has a 50-day moving average price of $22.24 and a 200-day moving average price of $21.06. Siemens Healthineers has a twelve month low of $19.20 and a twelve month high of $28.92.

About Siemens Healthineers

Siemens Healthineers AG is a Germany-based medical technology company that develops and supplies products, services and digital solutions for healthcare providers. Its portfolio supports medical imaging, laboratory diagnostics, cancer treatment, minimally invasive procedures and related clinical workflows.

The company’s imaging business offers magnetic resonance imaging, computed tomography, molecular imaging, X-ray and ultrasound systems. Its diagnostics activities include laboratory testing, point-of-care testing and diagnostic IT solutions.